Ovid Therapeutics Inc (OVID) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Ovid Therapeutics Inc

NASDAQ | OVID

0.30

USD

-0.0386 (-11.35%)

AT CLOSE (AS OF Apr 3, 2025)

$24M

MARKET CAP

P/E Ratio

-0.37

EPS

$3.5

52 Week High

$0.3

52 Week Low

LIFE SCIENCES

Sector

OVID Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

OVID Technicals

Tags:

OVID Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$29M
Total Revenue	$566K
Cost Of Revenue	$30M
Costof Goods And Services Sold	$613K
Operating Income	-$62M
Selling General And Administrative	$26M
Research And Development	$37M
Operating Expenses	$62M
Investment Income Net	$3.9M
Net Interest Income	$3.9M
Interest Income	$3.9M
Interest Expense	-
Non Interest Income	$566K
Other Non Operating Income	$35M
Depreciation	$400K
Depreciation And Amortization	$200K
Income Before Tax	-$26M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$26M
Comprehensive Income Net Of Tax	-$26M
Ebit	-$62M
Ebitda	-$62M
Net Income	-$26M

Revenue & Profitability

Earnings Performance

OVID Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$92M
Total Current Assets	$56M
Cash And Cash Equivalents At Carrying Value	$26M
Cash And Short Term Investments	$53M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$34M
Property Plant Equipment	$433K
Accumulated Depreciation Amortization Ppe	$1.4M
Intangible Assets	$100K
Intangible Assets Excluding Goodwill	$100K
Goodwill	-
Investments	$27M
Long Term Investments	$21M
Short Term Investments	$27M
Other Current Assets	$2.9M
Other Non Current Assets	$92K
Total Liabilities	$24M
Total Current Liabilities	$11M
Current Accounts Payable	$3.2M
Deferred Revenue	-
Current Debt	-
Short Term Debt	$1.3M
Total Non Current Liabilities	$13M
Capital Lease Obligations	$15M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$1.3M
Other Current Liabilities	$6M
Other Non Current Liabilities	-
Total Shareholder Equity	$68M
Treasury Stock	-
Retained Earnings	-$304M
Common Stock	$71K
Common Stock Shares Outstanding	$71M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$56M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$2.3M
Change In Operating Assets	-$899K
Depreciation Depletion And Amortization	$613K
Capital Expenditures	$161K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$26M
Cashflow From Investment	$55M
Cashflow From Financing	$622K
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$622K
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$26M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$29M
Total Revenue	$566K
Cost Of Revenue	$30M
Costof Goods And Services Sold	$613K
Operating Income	-$62M
Selling General And Administrative	$26M
Research And Development	$37M
Operating Expenses	$62M
Investment Income Net	$3.9M
Net Interest Income	$3.9M
Interest Income	$3.9M
Interest Expense	-
Non Interest Income	$566K
Other Non Operating Income	$35M
Depreciation	$400K
Depreciation And Amortization	$200K
Income Before Tax	-$26M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$26M
Comprehensive Income Net Of Tax	-$26M
Ebit	-$62M
Ebitda	-$62M
Net Income	-$26M

OVID Profile

Ovid Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	9.42%	-	742,693,504
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$5.99	1,796.17%	$26.40M	310,904
MKTW	$9.19	1,684.81%	$19.91M	117,875
MRM	$0.69	87.76%	$2.91M	53,662,982
PTIX	$0.42	84.14%	$4.04M	177,332,811
OSRH	$2.47	68.03%	$40.06M	89,471,971

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

OVID $0.30 (-11.35%) Quote details